Episode Details
Back to Episodes
Moderna’s Surge: Flu Vaccine & Beyond | Business and Finance News
Published 2 days, 6 hours ago
Description
Moderna’s stock soars 150% in a year fueled by FDA flu vaccine approval buzz and a bold pivot into cancer therapies—yet with a $26.7B valuation, zero profits, and years until treatments hit shelves, investors should tread carefully and wait for the hype to cool before betting big.
Listen in comfort:
Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn
Advertise on DNN:
advertise@thednn.ai
This is an automated, high-level news summary based on public reporting.
Report issues to feedback@thednn.ai.
View sources & latest updates:
https://sources.thednn.ai/b873fa7b06b7bb4f